PPS-exempt cancer hospitals are a small group of specialized cancer treatment centers in the United States that Congress permanently excused from Medicare’s standard hospital payment system. Since 1983, eleven hospitals have held this exemption, allowing them to receive Medicare reimbursement based largely on their reported costs rather than the fixed, diagnosis-based rates that govern virtually every other hospital in the country. The arrangement was designed to protect institutions focused exclusively on cancer from financial penalties that a one-size-fits-all payment formula might impose, but it has generated decades of debate over whether the extra spending translates into better care.
How Medicare Normally Pays Hospitals and Why Cancer Centers Got an Exception
When Medicare introduced the inpatient prospective payment system in 1983, it fundamentally changed how hospitals got paid. Instead of reimbursing whatever a hospital spent on a patient, Medicare began paying a predetermined amount tied to the patient’s diagnosis. Hospitals that treated patients for less than that amount kept the savings; hospitals that spent more absorbed the loss. The idea was to reward efficiency and rein in costs that had been climbing steeply through the 1970s.
Congress recognized almost immediately that this approach could hurt hospitals treating cancer patients almost exclusively. Cancer care tends to be expensive and highly variable. A hospital that sees a wide mix of patients can offset costly cancer cases with less complex ones, but a facility devoted entirely to oncology has no simpler cases to balance against. Lawmakers worried that the new fixed payments would systematically underpay these specialized institutions, so they wrote criteria allowing certain cancer hospitals to opt out of the PPS entirely.1Government Accountability Office. Medicare: Payment Methods For Certain Cancer Hospitals Should Be Revised To Promote Efficiency Eleven hospitals met those criteria, and the same eleven hold the exemption today. No new hospitals have been added since the program’s early years, and the list has remained effectively frozen.
How PPS-Exempt Cancer Hospitals Are Paid
The payment mechanics for these hospitals differ sharply from what other hospitals experience. For inpatient care, Medicare reimburses PPS-exempt cancer hospitals based on their reported costs, subject to an upper limit, along with potential add-on payments. For outpatient services, Medicare pays at service-specific rates but then applies an upward adjustment that, again, reflects each hospital’s reported costs.2U.S. Government Accountability Office. Medicare: Payment Methods For Certain Cancer Hospitals Should Be Revised To Promote Efficiency A cross-country comparison of hospital payment systems described this arrangement plainly: selected cancer hospitals in the United States are “completely excluded” from the diagnosis-based payment system and reimbursed on the basis of “reasonable costs.”3PubMed Central. How Denmark, England, Estonia, France, Germany, and the USA Pay for Variable, Specialized and Low Volume Care: A Cross-country Comparison of In-patient Payment Systems
Under a PPS, hospitals have a direct financial incentive to keep costs below the fixed payment. If they manage to deliver a hip replacement or a course of chemotherapy for less than Medicare’s rate, the hospital pockets the difference. Cost-based reimbursement flips that incentive. When a hospital is paid what it spends, there is little financial reason to find a cheaper way to deliver the same result. The Government Accountability Office has pointed this out repeatedly, noting that the exemption “provides little incentive for efficiency” compared with how PPS teaching hospitals are paid.4U.S. Government Accountability Office. Medicare: Payment Methods For Certain Cancer Hospitals Should Be Revised To Promote Efficiency
How Much More Medicare Spends at These Hospitals
The price difference is substantial. A GAO analysis using 2012 data estimated that PPS-exempt cancer hospitals received roughly 42 percent more in Medicare inpatient payments per discharge than what Medicare would have paid a local PPS teaching hospital to treat cancer patients with the same level of complexity. On the outpatient side, payments ran about 37 percent higher on average than what PPS teaching hospitals would have received for the same set of services.5Government Accountability Office. Medicare: Payment Methods For Certain Cancer Hospitals Should Be Revised To Promote Efficiency
Those percentages translate into real money. The comparison was not between a small rural hospital and a world-class cancer center. It was between PPS-exempt cancer hospitals and PPS teaching hospitals in the same geographic area treating beneficiaries with the same diagnoses. The gap reflects the payment methodology itself, not just differences in patient mix or geography. Whether that premium is justified remains the central policy question surrounding the exemption.
Do Patients at PPS-Exempt Cancer Hospitals Actually Do Better?
The outcomes picture is more encouraging for defenders of the exemption, though interpreting it requires some care. A study published in JAMA Oncology found that one-year mortality for patients treated at PPS-exempt hospitals was about ten percentage points lower than at community hospitals across all cancers, with the pattern persisting through five years of follow-up and across specific cancer types.6JAMA Oncology. Risk Adjusting Survival Outcomes in Hospitals That Treat Patients With Cancer Without Information on Cancer Stage That is a large gap, but comparing specialized cancer centers to community hospitals is a bit like comparing a Formula 1 pit crew to a neighborhood garage. Community hospitals treat cancer, but they are not built around it the way these eleven institutions are.
A more revealing comparison looked at PPS-exempt cancer centers alongside other NCI-designated cancer centers, which are themselves elite institutions. That study, published in JAMA Internal Medicine, found that the two groups were quite similar in hospital characteristics, cancer-related services, patient complexity, and nurse staffing. On adjusted postoperative outcomes, PPS-exempt cancer centers and NCI-designated cancer centers performed comparably on 15 of 18 measures, including mortality, readmission, and surgical site infections. Where differences did emerge, they slightly favored the PPS-exempt hospitals: patients at NCI-designated centers were more likely to experience postoperative sepsis, acute renal failure, and urinary tract infections.7PubMed Central. Comparison of Hospitals Affiliated With PPS-Exempt Cancer Centers, Other Hospitals Affiliated With NCI-Designated Cancer Centers, and Other Hospitals That Provide Cancer Care
When the same study compared PPS-exempt cancer centers against the broader universe of hospitals providing cancer care, the gap widened considerably. PPS-exempt status was associated with improved outcomes on 7 of 18 measures, including mortality, sepsis, acute renal failure, pulmonary failure, and failure to rescue.8PubMed Central. Comparison of Hospitals Affiliated With PPS-Exempt Cancer Centers, Other Hospitals Affiliated With NCI-Designated Cancer Centers, and Other Hospitals That Provide Cancer Care So these hospitals clearly outperform typical cancer-treating hospitals, but the advantage over other top-tier cancer centers is narrower than the payment premium might suggest.
Reputation Versus Measurable Quality
One interesting wrinkle in the data is the gap between how these hospitals are perceived and how they actually perform relative to other elite cancer centers. PPS-exempt cancer hospitals had dramatically higher U.S. News reputation scores than NCI-designated cancer centers. Yet the two groups showed no meaningful differences in oncology patient volume, patient safety ratings, nurse staffing, overall cancer scores, or survival scores.9PubMed Central. Comparison of Hospitals Affiliated With PPS-Exempt Cancer Centers, Other Hospitals Affiliated With NCI-Designated Cancer Centers, and Other Hospitals That Provide Cancer Care The brand recognition of institutions like MD Anderson, Memorial Sloan Kettering, and City of Hope is enormous, and it outpaces the measurable quality gap between them and other top cancer programs. For patients choosing where to seek treatment, this is worth knowing: other NCI-designated cancer centers deliver comparable outcomes on most measures, often at lower cost to Medicare and potentially at lower out-of-pocket cost as well.
Quality Reporting Requirements
For years, the cost-based payment model meant these hospitals faced fewer external accountability measures than PPS hospitals. That changed with the Affordable Care Act, which mandated a dedicated quality reporting program for the eleven PPS-exempt cancer hospitals. Starting in 2013, these institutions began publicly reporting on a small initial set of quality measures covering general patient safety and cancer-specific indicators for breast and colon cancer.10PubMed. Reporting of quality measures in gynecologic oncology programs at Prospective Payment System (PPS)-Exempt Cancer Hospitals: an early glimpse into a challenging initiative
The measure set has expanded over time. Subsequent rulemaking from CMS has revised and added quality reporting requirements, with updates tied to broader legislative vehicles like the 21st Century Cures Act and the Bipartisan Budget Act of 2018.11PubMed Central. Medicare Program; Hospital Inpatient Prospective Payment Systems for Acute Care Hospitals and the Long-Term Care Hospital Prospective Payment System and Policy Changes and Fiscal Year 2019 Rates; Quality Reporting Requirements for Specific Providers Still, the reporting program does not tie payment to performance the way value-based purchasing programs do for PPS hospitals. These hospitals report quality data, but their payment is not docked or boosted based on how they score. The accountability is informational, not financial.
The Efficiency Argument and Why It Keeps Resurfacing
Critics of the exemption, including the GAO and the Medicare Payment Advisory Commission, have argued for years that the cost-based payment model should be reformed. The GAO’s recommendation has been straightforward: revise the payment methods for these hospitals to promote efficiency.12Government Accountability Office. Medicare: Payment Methods For Certain Cancer Hospitals Should Be Revised To Promote Efficiency From a policy standpoint, paying 40 percent more for comparable or modestly better outcomes is hard to justify when Medicare faces persistent budget pressure.
Defenders counter that the exemption supports a research and treatment infrastructure that cannot easily be replicated under fixed payments. These hospitals often treat the most complex cancer cases, participate in a disproportionate share of early-phase clinical trials, and develop innovations that eventually benefit patients everywhere. A cost-based reimbursement system, they argue, gives these institutions the financial flexibility to take on patients and research projects that a PPS hospital might find economically unattractive. The debate is not purely about today’s costs but about whether constraining these hospitals’ revenue would erode their capacity to advance cancer treatment more broadly.
Neither side has fully won the argument in Congress. Several budget proposals over the years have floated gradually transitioning these hospitals to the PPS, but the exemption has survived each time. The hospitals themselves are politically influential, well-known to the public, and located across enough congressional districts to maintain a base of legislative support. Meanwhile, the number of hospitals affected is so small, just eleven, that the total cost to Medicare, while significant in aggregate, does not rank among the program’s largest spending categories.
What This Means If You Are a Cancer Patient
If you are diagnosed with cancer and considering treatment at one of these eleven hospitals, there are a few practical things to understand. First, the PPS exemption is a Medicare billing designation, not a quality certification. It does not mean these hospitals are officially ranked higher than other cancer centers. Several NCI-designated cancer centers that operate under the standard PPS deliver outcomes that are statistically indistinguishable from PPS-exempt hospitals on most quality metrics.
Second, the cost-based reimbursement model affects Medicare’s spending, but it can also affect your out-of-pocket costs depending on your insurance structure. Medicare beneficiaries treated at these hospitals may face different coinsurance amounts because the underlying payment rates are higher. If you have supplemental insurance that covers those costs, the difference may be invisible to you. If you do not, it could matter.
Third, these hospitals tend to have deep expertise in specific cancer types and often have access to clinical trials that smaller centers do not offer. For rare or unusually complex cancers, the concentration of subspecialty expertise can be genuinely valuable in ways that do not always show up in broad surgical outcome measures. The 18-measure comparison cited earlier captures postoperative complications well, but it does not capture whether a particular hospital has a world expert in your specific cancer subtype or an open trial of a promising new therapy.
How the US Approach Compares Internationally
Most countries that use diagnosis-based hospital payment systems do not carve out permanent exemptions for cancer hospitals. A six-country comparison found that while several nations have mechanisms for handling variable, specialized, or low-volume care, the American approach of completely excluding selected cancer hospitals from the payment system and reimbursing on reasonable costs is distinctive.13PubMed Central. How Denmark, England, Estonia, France, Germany, and the USA Pay for Variable, Specialized and Low Volume Care: A Cross-country Comparison of In-patient Payment Systems Other countries typically handle high-cost specialty care through add-on payments, supplemental funding streams, or adjusted rates within the existing payment framework rather than by removing certain hospitals from the system entirely.
This matters because it illustrates that there are alternative policy designs. You can protect specialized cancer care financially without fully exempting hospitals from cost discipline. Whether those alternatives would work in the American context, with its particular mix of academic medical centers, private insurers, and political dynamics, is a separate question. But the international experience suggests the current US approach is a policy choice, not a necessity dictated by the nature of cancer care itself.
The Frozen List Problem
One peculiarity that rarely gets discussed is that the list of eleven hospitals has not changed meaningfully since the criteria were established in the 1980s. Cancer care has transformed dramatically since then. Genomic medicine, immunotherapy, targeted therapy, and proton beam facilities have proliferated far beyond these eleven institutions. Dozens of NCI-designated comprehensive cancer centers now exist, many of which rival the PPS-exempt hospitals in clinical volume, research output, and subspecialty depth.
Yet the exemption is not available to them. The criteria for qualifying were set decades ago, and no new hospital has successfully entered the group. This creates an odd dynamic: the payment privilege is frozen in time even as the landscape of cancer care has evolved around it. A hospital that opened in 1990 and built itself into a world-class cancer center from scratch would operate under the PPS, while a hospital that happened to meet the criteria in 1983 continues to enjoy cost-based reimbursement regardless of whether the original justification still applies to the same degree. Whether this frozen-list design is fair or rational is, like most things about the exemption, a matter that has been debated without resolution for years.